Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96IS3
UPID:
RAX2_HUMAN
Alternative names:
Q50-type retinal homeobox protein; Retina and anterior neural fold homeobox-like protein 1
Alternative UPACC:
Q96IS3
Background:
Retina and anterior neural fold homeobox protein 2, also known as Q50-type retinal homeobox protein, plays a crucial role in the modulation of photoreceptor specific genes. It binds to elements within the rhodopsin promoter, highlighting its significance in retinal development and function.
Therapeutic significance:
Linked to age-related macular degeneration, cone-rod dystrophy 11, and retinitis pigmentosa 95, this protein's understanding could pave the way for innovative treatments targeting these debilitating eye diseases.